Champions Biotechnlg (CSBR) 0.6900 $CSBR
Data from Study of Champions Oncology TumorGrafts to be Presented at European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Wed Sep 24, 7:55AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that data from a study of Champions' TumorGrafts® will be presented on Monday, Sept. 29, at the European Society for Medical Oncology (ESMO) 2014 Congress.
Champions Oncology posts higher loss from operations for Q1 2014
M2 - Fri Sep 12, 7:17AM CDT
Oncology drug company Champions Oncology (Other OTC:CSBR) Thursday reported its loss from operations of USD3.7m for the first quarter of 2015.
Champions Oncology Reports Results for the First Quarter Ended July 31, 2014
PR Newswire - Thu Sep 11, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2014.
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 11
PR Newswire - Tue Sep 09, 9:43AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2014, on Thursday, September 11, 2014, after market close.
Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014
PR Newswire - Thu Jul 24, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24
PR Newswire - Mon Jul 21, 4:28PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014, on Thursday, July 24, 2014, after market close.
Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer
PR Newswire - Tue Jun 17, 7:00AM CDT
Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2014
PR Newswire - Thu Mar 13, 3:28PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fiscal third quarter ended January 31, 2014.
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 13
PR Newswire - Mon Mar 10, 9:45AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2014 on Thursday, March 13, 2014, after market close.
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"
, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.
Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA" certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor.
Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
Data from Study of Champions Oncology TumorGrafts to be Presented at European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Wed Sep 24, 7:55AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that data from a study of Champions' TumorGrafts® will be presented on Monday, Sept. 29, at the European Society for Medical Oncology (ESMO) 2014 Congress.
Champions Oncology posts higher loss from operations for Q1 2014
M2 - Fri Sep 12, 7:17AM CDT
Oncology drug company Champions Oncology (Other OTC:CSBR) Thursday reported its loss from operations of USD3.7m for the first quarter of 2015.
Champions Oncology Reports Results for the First Quarter Ended July 31, 2014
PR Newswire - Thu Sep 11, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2014.
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 11
PR Newswire - Tue Sep 09, 9:43AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2014, on Thursday, September 11, 2014, after market close.
Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014
PR Newswire - Thu Jul 24, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24
PR Newswire - Mon Jul 21, 4:28PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014, on Thursday, July 24, 2014, after market close.
Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer
PR Newswire - Tue Jun 17, 7:00AM CDT
Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2014
PR Newswire - Thu Mar 13, 3:28PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fiscal third quarter ended January 31, 2014.
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 13
PR Newswire - Mon Mar 10, 9:45AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2014 on Thursday, March 13, 2014, after market close.
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"
, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds. Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA"
certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor. Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
